Vanqua Bio
Eric Zluhan has a diverse work experience beginning in 2007 when they worked as a Media Specialist at Best Buy. Eric then worked as a Sales Associate at Plan Nine in 2009. From 2013 to 2015, they held a variety of roles including a Research Intern at SUNY Upstate Medical University, a Laboratory Technician at Bayer, and a Research Assistant at Ichor Therapeutics, Inc. where they adapted stem cell differentiation protocol into robot-compatible method, then automated method on Biomek series liquid handling robot. From 2015 to 2020, they worked as a Graduate Research Assistant at Upstate Medical University where they characterized a new role for the Reelin signaling pathway using primary neuronal cultures, cortical explants and mouse models. Eric also wrote macros to expedite morphological quantification and developed custom neurite-outgrowth assays. Currently, they are a Senior Scientist at Vanqua Bio.
Eric Zluhan earned their Bachelor's degree in Biology/Biological Sciences, General from Maryville University of Saint Louis between 2009 and 2013. Eric then went on to pursue a Doctor of Philosophy (Ph.D.) in Neuroscience at State University of New York Upstate Medical University, which they completed in 2020.
Vanqua Bio
Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).